“Stem-cell-derived” skin care
This article was originally published in The Rose Sheet
Executive Summary
Proteonomix's line of "stem-cell-derived" anti-aging cosmetics will debut in first quarter of 2009, biotech firm announces Oct. 8. The serum, day cream, night cream, cleanser and exfoliator rely on a proprietary matrix of proteins called Matrix NC-138 - derived from culture medium of non-embryonic, human stem cell derivatives - to stimulate collagen production, which leads to a reduction of wrinkles, company says. Subsidiary Proteoderm's anti-aging solutions "can bring patients higher satisfaction and results, working to revitalize and rejuvenate cells to help drastically reverse the effects of aging," according to the release. Line will be distributed through physicians' offices. Firm changed its name from National Stem Cell Holdings to Proteonomix in September (1"The Rose Sheet" Sept. 1, 2008, In Brief)
You may also be interested in...
Stem-Cell-Based Anti-Aging Ingredient Under Development, Biotech Firm Says
A biotech firm that specializes in therapeutic products derived from human stem cells has a skin rejuvenation ingredient in the works, according to International Stem Cell Corporation's April 21 release
NSCH becomes Proteonomix
Biotech firm National Stem Cell Holdings announces name change to Proteonomix and change of trading symbol from NHGI to PROTD, makes official its focus on proteomics and its movement from strict R&D to commercial product development. In July, the company introduced its new cosmeceutical line featuring "unique natural matrix of proteins called Secreted Matrix and Matrix NC-138" through subsidiary Proteoderm, whose first public display of the skin-care products at recent International Anti-Aging Conference in Washington D.C. met with an "encouraging response." Proteoderm has plans for "an extensive array of specialty skin-care products" formulated with its proprietary proteins derived from non-embryonic stem cells," according to the release. Protenomix believes it now is in a position to raise capital in "very challenging financial environment for product commercialization.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”